Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University of Minnesota
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07263022CT.gov Cognitive Strategies in Early Psychosis 2 | — | Not Yet Recruiting | — | — | — |
NCT05046353CT.gov D-serine AudRem: R33 Phase | — | Suspended | — | — | — |
NCT03711500CT.gov D-serine Augmentation of Neuroplasticity | — | Completed | — | — | — |
NCT02156908CT.gov D-serine and Cognitive Remediation in Schizophrenia | — | Completed | — | — | — |
NCT01474395CT.gov N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia | — | Unknown | — | — | — |
NCT01459029CT.gov High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia | — | Unknown | — | — | — |
NCT00816894CT.gov D-serine Monotherapy for Schizophrenia | — | Completed | — | — | — |
NCT00322023CT.gov Safety and Effectiveness of D-serine in Schizophrenia | — | Completed | — | — | — |
NCT00237848CT.gov D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia | — | Completed | — | — | — |
NCT00491569CT.gov Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT00138775CT.gov Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia | — | Unknown | — | — | — |
NCT00237809CT.gov D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia | — | Completed | — | — | — |
NCT00215917CT.gov D-Serine Monotherapy for Schizophrenia | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Serine D-Form (this asset) | University of Minnesota | P3 | BB · 66 |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Raloxifene | Shanghai Mental Health Center | P4 | BBB |
| Roluperidone | Minerva Neurosciences | P3 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Serine D-Form
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizoaffective Disorder | — | P3 | BBB · 72 |
| Psychotic Disorder | — | P3 | B · 63 |
| Parkinson Disease | — | P4 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Serine D-Form in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/serine-d-form-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →